Abstract
BackgroundNephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis. This study aimed to evaluate the relation between serum OPG, RANKL concentration, and bone mineral density (BMD) in patients with kidney stone disease.MethodsForty-four nephrolithiasis patients with either low bone mass or normal BMD (considered control group) were enrolled in this study. BMD was measured at lumbar spine (L1-L4) and femoral neck by dual-energy X-ray absorptiometry (DEXA). The serum OPG and RANKL were determined using the ELISA method.ResultsThe median levels of serum OPG were significantly higher in nephrolithiasis patients with low bone mass compared to the nephrolithiasis patients with normal BMD (3.9 pmol/l versus 3.1 pmol/l; P = 0.03), respectively. Negative correlation was detected between bone densities of femoral neck and OPG in patients with nephrolithiasis (r = −.0344, P = 0.02).ConclusionThe present study showed that high serum fasting OPG levels may be indicative of femoral neck BMD in patients with nephrolithiasis.
Highlights
Nephrolithiasis is a risk factor for Osteopenia and osteoporosis
Several in vitro and rodent studies have revealed that proinflammatory cytokines such as interleukin-6 (IL-6), interleukin-1 (IL-1), and tumor necrosis factor-alpha (TNF-α) are involved in the pathogenesis of osteoporosis
The aim of this study was to define the role of Receptor activator of nuclear factor kappaB ligand (RANKL) and OPG in the development of nephrolithiasis- related reduced bone mineral density
Summary
Nephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis. This study aimed to evaluate the relation between serum OPG, RANKL concentration, and bone mineral density (BMD) in patients with kidney stone disease. A number of studies have provided evidence for the association between kidney stone and lower BMD. Several in vitro and rodent studies have revealed that proinflammatory cytokines such as interleukin-6 (IL-6), interleukin-1 (IL-1), and tumor necrosis factor-alpha (TNF-α) are involved in the pathogenesis of osteoporosis. The aim of this study was to define the role of RANKL and OPG in the development of nephrolithiasis- related reduced bone mineral density. We compared nephrolithiasis patients with low bone mass to nephrolithiasis patients with normal BMD to identify risk factors for the development of low bone mass in such patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
